Korea cuts back ScoMo’s dodgy vaccine

Advertisement

Readers will recall that the process behind the Morrison’s Government choice of vaccine posed some sticky questions:

Advertisement

Since then we have seen:

  • Questionable results when AZ accidentally administered the wrong doses to its trial patients.
  • Much lower efficacy of 62% than alternatives, though that is still not bad in the scheme of things.
  • It has run afoul of church groups because it uses aborted fetal cells in production.
  • South Africa cutting it because it is ineffective against that strain.

Today, there is more bad news with South Korea winding back its use:

  • For the elderly owing to production problems.
  • And to wait for greater clarity on its efficacy in the elderly.
Advertisement

AZ has begun work on adapting the vaccine to address the new variants.

Basically, other than ScoMo’s mate running AZ, the other features of its vaccine is that it is cheap, as well as easy to produce and transport:

Advertisement

And for those of you waiting to pounce on me for arguing this morning that we should make vaccines mandatory for the elderly, remember I said they should have a choice of which one!

About the author
David Llewellyn-Smith is Chief Strategist at the MB Fund and MB Super. David is the founding publisher and editor of MacroBusiness and was the founding publisher and global economy editor of The Diplomat, the Asia Pacific’s leading geo-politics and economics portal. He is also a former gold trader and economic commentator at The Sydney Morning Herald, The Age, the ABC and Business Spectator. He is the co-author of The Great Crash of 2008 with Ross Garnaut and was the editor of the second Garnaut Climate Change Review.